US 12,472,243 B2
Combined vaccine against human respiratory syncytial virus (RSV) infections and method thereof for inducing immune response
Jinsheng He, Beijing (CN); Lin Du, Beijing (CN); Yuanhui Fu, Beijing (CN); Weihua Zhu, Beijing (CN); Xianglei Peng, Beijing (CN); Bo Gao, Beijing (CN); Yanpeng Zheng, Beijing (CN); and Meiqin Liu, Beijing (CN)
Assigned to BEIJING JIAOTONG UNIVERSITY, Beijing (CN); and BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL CO., LTD., Beijing (CN)
Appl. No. 17/768,074
Filed by BEIJING JIAOTONG UNIVERSITY, Beijing (CN); and BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL CO., LTD., Beijing (CN)
PCT Filed Aug. 11, 2021, PCT No. PCT/CN2021/111960
§ 371(c)(1), (2) Date Apr. 11, 2022,
PCT Pub. No. WO2022/042300, PCT Pub. Date Mar. 3, 2022.
Claims priority of application No. 202010863764.9 (CN), filed on Aug. 25, 2020.
Prior Publication US 2024/0091334 A1, Mar. 21, 2024
Int. Cl. A61K 39/12 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); A61P 37/04 (2018.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/70 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A combined vaccine against human respiratory syncytial virus (RSV) infection, comprising: a first composition and a second composition, wherein
the first composition comprises an immunologically effective dosage of a replication-deficient human adenovirus type 26 vector and a pharmaceutically acceptable vector, and the replication-deficient human adenovirus type 26 vector comprises a nucleotide encoding an antigenic protein of RSV;
the second composition comprises an immunologically effective dosage of a replication-deficient chimpanzee adenovirus type 63 vector and a pharmaceutically acceptable vector, and the replication-deficient chimpanzee adenovirus type 63 vector comprises a nucleotide encoding an antigenic protein of RSV; and
the first composition is a primary immunization composition and the second composition is a booster immunization composition; alternatively, the first composition is the booster immunization composition, and the second composition is the primary immunization composition,
wherein in the first composition, the replication-deficient human adenovirus type 26 vector comprises a nucleotide encoding an attachment glycoprotein 130-230aa (G 130-230) of RSV, the nucleotide sequence of which is set forth in SEQ ID NO: 2: or
wherein in the first composition, the replication-deficient human adenovirus type 26 vector comprises a nucleotide encoding both a pre-fusion fusion glycoprotein (preF) and G 130-230 of RSV, the nucleotide sequence of which is set forth in SEQ ID NO: 3.